Please check your internet connection and try again.
# Tradjenta (linagliptin)
## Overview
Linagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used to improve glycemic control in adults with type 2 diabetes mellitus. It works by increasing incretin levels, which leads to increased insulin release and decreased glucagon secretion in a glucose-dependent manner.
## Primary Indications
* Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
* Can be used as monotherapy or in combination with other antidiabetic agents, including metformin, sulfonylureas, thiazolidinediones (TZDs), sodium-glucose cotransporter-2 (SGLT2) inhibitors, and insulin.
## Adult Dosing
* The recommended dose of linagliptin is **5 mg once daily**.
* Linagliptin can be taken with or without food.
## Pediatric Dosing
* The safety and efficacy of linagliptin in pediatric patients have not been established.
## Dose Adjustments
* No dose adjustment is required for patients with mild, moderate, or severe renal impairment.
* No dose adjustment is required for patients with any degree of hepatic impairment.
## Contraindications
* Hypersensitivity to linagliptin or any excipients in the formulation.
## Adverse Effects
The most common adverse effects include:
* Hypoglycemia (especially when used in combination with sulfonylureas or insulin)
* Diarrhea
* Nasopharyngitis
* Cough
Serious adverse effects reported include:
* Pancreatitis
* Severe and disabling arthralgia (joint pain)
* Bullous pemphigoid
## Key Drug Interactions
* **CYP3A4 Inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's wort):** May decrease linagliptin exposure and efficacy. Concurrent use is not recommended.
* **Sulfonylureas and Insulin:** Increased risk of hypoglycemia. Dose reduction of the sulfonylurea or insulin may be necessary.
## Monitoring
* **Blood Glucose:** Monitor fasting plasma glucose and HbA1c to assess glycemic control and efficacy.
* **Renal Function:** Routine monitoring is not required, but assess renal function if indicated.
* **Signs/Symptoms of Pancreatitis:** Educate patients to report persistent, severe abdominal pain.
* **Signs/Symptoms of Hypoglycemia:** Especially when used with sulfonylureas or insulin.
## Clinical Pearls
* Linagliptin is unique among DPP-4 inhibitors as it does not require dose adjustment for renal or hepatic impairment.
* It is eliminated primarily via the hepatobiliary system and does not accumulate in patients with renal impairment.
* Caution is advised when initiating linagliptin in patients with a history of pancreatitis.
* Patients should be educated about the signs and symptoms of hypoglycemia and hypersensitivity reactions.
***
*This information is intended for healthcare professionals and does not substitute for comprehensive prescribing information. Always consult the most current official prescribing information or a reliable drug information resource for complete and up-to-date guidance.*
